The smart insulin pens market size has grown strongly in recent years. It will grow from $0.11 billion in 2025 to $0.12 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rising prevalence of diabetes, increasing insulin-dependent patient population, growing awareness of dose accuracy, expansion of home healthcare solutions, availability of digital health platforms.
The smart insulin pens market size is expected to see strong growth in the next few years. It will grow to $0.16 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing integration with digital diabetes ecosystems, rising adoption of personalized insulin therapy, expansion of remote patient monitoring, growing focus on data-driven diabetes care, increasing investments in smart drug delivery technologies. Major trends in the forecast period include increasing adoption of connected insulin delivery devices, rising use of real-time dose tracking solutions, growing demand for home-based diabetes management, expansion of mobile app-integrated insulin pens, enhanced focus on patient adherence and safety.
The expanding global diabetic population is anticipated to accelerate the growth of the smart insulin pen market in the coming years. The diabetic population comprises individuals diagnosed with diabetes, a chronic metabolic disorder marked by persistently high blood glucose levels. The rise in diabetes prevalence is largely attributed to increasing obesity rates and sedentary lifestyles worldwide, which are key contributors to Type 2 diabetes. Smart insulin pens support improved diabetes care by enabling accurate insulin dose tracking, providing reminders, and integrating treatment data, thereby enhancing medication adherence and supporting better glycemic control. For example, in 2025, data from the International Diabetes Federation indicated that in 2024, approximately 589 million adults aged 20-79 were living with diabetes, with projections estimating this number to rise to 853 million by 2050, and more than four out of five adults with diabetes residing in low- and middle-income countries. As a result, the growing global burden of diabetes is fueling the adoption of smart insulin pens.
Leading companies in the smart insulin pen space are focusing on the development of integrated solutions that combine real-time glucose monitoring, automated dose calculations, and missed-dose detection to streamline insulin therapy and minimize the risk of hypoglycemia. These systems integrate Bluetooth-enabled insulin pens, mobile applications, and compact continuous glucose monitoring devices to deliver personalized dosing recommendations, identify dosing errors, and support improved glycemic outcomes. For instance, in December 2024, Medtronic, a United States-based medical technology company, introduced its Smart MDI System, which pairs a smart insulin pen with the Simplera continuous glucose monitor to provide real-time, individualized dosing guidance. The system uniquely offers missed-meal dose detection and corrective recommendations, enabling users to address skipped or incorrect injections. Real-world evidence showed that patients who consistently acted on these alerts achieved Time in Range levels of approximately 67-71%, highlighting the capability of such technologies to enhance glucose management.
In October 2023, Novo Nordisk A/S acquired Biocorp, a France-based medical device company specializing in the development and manufacturing of drug-delivery systems and medical devices, for $164.5 million. This acquisition is expected to enable Novo Nordisk to further invest in Biocorp's device development and expedite its ambitions within devices and delivery solutions.
Major companies operating in the smart insulin pens market are Companion Medical, Novo Nordisk A/S, F. Hoffmann-La Roche AG, Emperra GmbH E-Health Technologies, Diamesco Co. Ltd., Digital Medics Pvt Ltd., Bigfoot Biomedical, Diabnext, Insulet Corporation, Sanofi India, Becton Dickinson, Biocon Ltd, Johnson & Johnson, Terumo, NIPRO, Medtronic PLC, Ypsomed Holding AG, Patients Pending Ltd, Dexcom, Insujet, Eli Lilly, Abbott Laboratories, Tandem Diabetes Care Inc.
North America was the largest region in the smart insulin pens market in 2025. Western Europe was the second largest region in the global smart insulin pens market share. The regions covered in the smart insulin pens market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the smart insulin pens market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the smart insulin pens market by increasing costs of imported electronic sensors, microchips, batteries, and precision plastic components used in connected pen devices. Healthcare providers and patients in North America and Europe are most affected due to reliance on imported electronics, while Asia-Pacific faces higher manufacturing costs. These tariffs are increasing device prices and slowing adoption in cost-sensitive markets. However, they are also encouraging local device assembly, regional electronics sourcing, and innovation in cost-efficient smart insulin delivery solutions.
The smart insulin pens market research report is one of a series of new reports that provides smart insulin pens market statistics, including smart insulin pens industry global market size, regional shares, competitors with a smart insulin pens market share, detailed smart insulin pens market segments, market trends and opportunities, and any further data you may need to thrive in the smart insulin pens industry. This smart insulin pens market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Smart insulin pens refer to insulin delivery devices designed to monitor and record dosage information, including volume, time, and type. Additionally, these devices may offer functionalities such as generating reports for sharing with healthcare professionals.
Two primary types of smart insulin pens exist first-generation pens and second-generation pens (equipped with Bluetooth or USB connectivity). Second-generation smart insulin pens incorporate Bluetooth or USB features to facilitate closer monitoring. These pens come in either prefilled or reusable forms and are utilized for the treatment of both type 1 diabetes and type 2 diabetes. Smart insulin pens find application across various end-users, including hospitals and clinics, ambulatory surgical centers, as well as home care settings.
The smart insulins pens market consists of sales of instruments such as first-generation pens and second-generation pens (Bluetooth enabled, USB connected). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The smart insulin pens market size is expected to see strong growth in the next few years. It will grow to $0.16 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to increasing integration with digital diabetes ecosystems, rising adoption of personalized insulin therapy, expansion of remote patient monitoring, growing focus on data-driven diabetes care, increasing investments in smart drug delivery technologies. Major trends in the forecast period include increasing adoption of connected insulin delivery devices, rising use of real-time dose tracking solutions, growing demand for home-based diabetes management, expansion of mobile app-integrated insulin pens, enhanced focus on patient adherence and safety.
The expanding global diabetic population is anticipated to accelerate the growth of the smart insulin pen market in the coming years. The diabetic population comprises individuals diagnosed with diabetes, a chronic metabolic disorder marked by persistently high blood glucose levels. The rise in diabetes prevalence is largely attributed to increasing obesity rates and sedentary lifestyles worldwide, which are key contributors to Type 2 diabetes. Smart insulin pens support improved diabetes care by enabling accurate insulin dose tracking, providing reminders, and integrating treatment data, thereby enhancing medication adherence and supporting better glycemic control. For example, in 2025, data from the International Diabetes Federation indicated that in 2024, approximately 589 million adults aged 20-79 were living with diabetes, with projections estimating this number to rise to 853 million by 2050, and more than four out of five adults with diabetes residing in low- and middle-income countries. As a result, the growing global burden of diabetes is fueling the adoption of smart insulin pens.
Leading companies in the smart insulin pen space are focusing on the development of integrated solutions that combine real-time glucose monitoring, automated dose calculations, and missed-dose detection to streamline insulin therapy and minimize the risk of hypoglycemia. These systems integrate Bluetooth-enabled insulin pens, mobile applications, and compact continuous glucose monitoring devices to deliver personalized dosing recommendations, identify dosing errors, and support improved glycemic outcomes. For instance, in December 2024, Medtronic, a United States-based medical technology company, introduced its Smart MDI System, which pairs a smart insulin pen with the Simplera continuous glucose monitor to provide real-time, individualized dosing guidance. The system uniquely offers missed-meal dose detection and corrective recommendations, enabling users to address skipped or incorrect injections. Real-world evidence showed that patients who consistently acted on these alerts achieved Time in Range levels of approximately 67-71%, highlighting the capability of such technologies to enhance glucose management.
In October 2023, Novo Nordisk A/S acquired Biocorp, a France-based medical device company specializing in the development and manufacturing of drug-delivery systems and medical devices, for $164.5 million. This acquisition is expected to enable Novo Nordisk to further invest in Biocorp's device development and expedite its ambitions within devices and delivery solutions.
Major companies operating in the smart insulin pens market are Companion Medical, Novo Nordisk A/S, F. Hoffmann-La Roche AG, Emperra GmbH E-Health Technologies, Diamesco Co. Ltd., Digital Medics Pvt Ltd., Bigfoot Biomedical, Diabnext, Insulet Corporation, Sanofi India, Becton Dickinson, Biocon Ltd, Johnson & Johnson, Terumo, NIPRO, Medtronic PLC, Ypsomed Holding AG, Patients Pending Ltd, Dexcom, Insujet, Eli Lilly, Abbott Laboratories, Tandem Diabetes Care Inc.
North America was the largest region in the smart insulin pens market in 2025. Western Europe was the second largest region in the global smart insulin pens market share. The regions covered in the smart insulin pens market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the smart insulin pens market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the smart insulin pens market by increasing costs of imported electronic sensors, microchips, batteries, and precision plastic components used in connected pen devices. Healthcare providers and patients in North America and Europe are most affected due to reliance on imported electronics, while Asia-Pacific faces higher manufacturing costs. These tariffs are increasing device prices and slowing adoption in cost-sensitive markets. However, they are also encouraging local device assembly, regional electronics sourcing, and innovation in cost-efficient smart insulin delivery solutions.
The smart insulin pens market research report is one of a series of new reports that provides smart insulin pens market statistics, including smart insulin pens industry global market size, regional shares, competitors with a smart insulin pens market share, detailed smart insulin pens market segments, market trends and opportunities, and any further data you may need to thrive in the smart insulin pens industry. This smart insulin pens market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Smart insulin pens refer to insulin delivery devices designed to monitor and record dosage information, including volume, time, and type. Additionally, these devices may offer functionalities such as generating reports for sharing with healthcare professionals.
Two primary types of smart insulin pens exist first-generation pens and second-generation pens (equipped with Bluetooth or USB connectivity). Second-generation smart insulin pens incorporate Bluetooth or USB features to facilitate closer monitoring. These pens come in either prefilled or reusable forms and are utilized for the treatment of both type 1 diabetes and type 2 diabetes. Smart insulin pens find application across various end-users, including hospitals and clinics, ambulatory surgical centers, as well as home care settings.
The smart insulins pens market consists of sales of instruments such as first-generation pens and second-generation pens (Bluetooth enabled, USB connected). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Smart Insulin Pens Market Characteristics
3. Smart Insulin Pens Market Supply Chain Analysis
4. Global Smart Insulin Pens Market Trends and Strategies
5. Smart Insulin Pens Market Analysis of End Use Industries
7. Global Smart Insulin Pens Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Smart Insulin Pens Total Addressable Market (TAM) Analysis for the Market
9. Smart Insulin Pens Market Segmentation
10. Smart Insulin Pens Market Regional and Country Analysis
11. Asia-Pacific Smart Insulin Pens Market
12. China Smart Insulin Pens Market
13. India Smart Insulin Pens Market
14. Japan Smart Insulin Pens Market
15. Australia Smart Insulin Pens Market
16. Indonesia Smart Insulin Pens Market
17. South Korea Smart Insulin Pens Market
18. Taiwan Smart Insulin Pens Market
19. South East Asia Smart Insulin Pens Market
20. Western Europe Smart Insulin Pens Market
21. UK Smart Insulin Pens Market
22. Germany Smart Insulin Pens Market
23. France Smart Insulin Pens Market
24. Italy Smart Insulin Pens Market
25. Spain Smart Insulin Pens Market
26. Eastern Europe Smart Insulin Pens Market
27. Russia Smart Insulin Pens Market
28. North America Smart Insulin Pens Market
29. USA Smart Insulin Pens Market
30. Canada Smart Insulin Pens Market
31. South America Smart Insulin Pens Market
32. Brazil Smart Insulin Pens Market
33. Middle East Smart Insulin Pens Market
34. Africa Smart Insulin Pens Market
36. Smart Insulin Pens Market Competitive Landscape and Company Profiles
37. Smart Insulin Pens Market Other Major and Innovative Companies
40. Smart Insulin Pens Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Smart Insulin Pens Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses smart insulin pens market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for smart insulin pens? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The smart insulin pens market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: First Generation Pens; Second Generation Pens2) By Usability: Prefilled; Reusable
3) By Application: Type 1 Diabetes; Type 2 Diabetes
4) By End User: Hospitals & Clinics; Ambulatory Surgical Centres; Home Care Settings
Subsegments:
1) By First Generation Pens: Basic Smart Insulin Pens With Standard Features; Simple Connectivity to Mobile Apps for Tracking and Logging Insulin Doses2) By Second Generation Pens: Advanced Smart Insulin Pens With Enhanced Features; Real-Time Data Sharing With Healthcare Providers and Caregivers; Sophisticated Mobile Applications for Comprehensive Diabetes Management
Companies Mentioned: Companion Medical; Novo Nordisk A/S; F. Hoffmann-La Roche AG; Emperra GmbH E-Health Technologies; Diamesco Co. Ltd.; Digital Medics Pvt Ltd.; Bigfoot Biomedical; Diabnext; Insulet Corporation; Sanofi India; Becton Dickinson; Biocon Ltd; Johnson & Johnson; Terumo; NIPRO; Medtronic PLC; Ypsomed Holding AG; Patients Pending Ltd; Dexcom; Insujet; Eli Lilly; Abbott Laboratories; Tandem Diabetes Care Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Smart Insulin Pens market report include:- Companion Medical
- Novo Nordisk A/S
- F. Hoffmann-La Roche AG
- Emperra GmbH E-Health Technologies
- Diamesco Co. Ltd.
- Digital Medics Pvt Ltd.
- Bigfoot Biomedical
- Diabnext
- Insulet Corporation
- Sanofi India
- Becton Dickinson
- Biocon Ltd
- Johnson & Johnson
- Terumo
- NIPRO
- Medtronic PLC
- Ypsomed Holding AG
- Patients Pending Ltd
- Dexcom
- Insujet
- Eli Lilly
- Abbott Laboratories
- Tandem Diabetes Care Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 0.12 Billion |
| Forecasted Market Value ( USD | $ 0.16 Billion |
| Compound Annual Growth Rate | 6.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 24 |
